Materials • Major Chemicals
$73.85 ▲ +0.08
(+0.11%)
MKT CAP: $3.81B • VOL: 392.3K
52W L $58 52W H $95
ROARABLE / RQD
B+ • 77/100
PIOTROSKI
7 / 9
CBT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-09-30 | FY 2024
FILED 2024-09-30 | FY 2023
FILED 2023-09-30 |
|---|---|---|---|
| Revenue (Total Sales) | $3.71B | $3.99B | $3.93B |
| YoY Revenue Growth % | -7.0% | +1.6% | — |
| Gross Profit | $940.0M | $960.0M | — |
| Gross Margin % | 25.3% | 24.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $621.0M | $614.0M | $526.0M |
| Operating Margin % | 16.7% | 15.4% | 13.4% |
| Net Income (GAAP) | $331.0M | $380.0M | $445.0M |
| EBITDA (Normalized) | $840.2M | $806.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $665.0M | $692.0M | $595.0M |
| Capital Expenditures (CapEx) | $274.0M | $241.0M | — |
| Free Cash Flow (FCF) | $391.0M | $451.0M | $595.0M |
| FCF Margin % | 10.5% | 11.3% | 15.1% |
| Return on Invested Capital (ROIC %) | 22.3% | 21.3% | — |
| Cash & Short-Term Equivalents | $230.0M | $183.0M | — |
| Total Debt (Short + Long Term) | $854.0M | $1.09B | — |
| Total Stockholders' Equity | $1.57B | $1.37B | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CBT.